Galmed Pharmaceuticals Ltd. (GLMD): Net earnings per share growth forecast for next year

Galmed Pharmaceuticals operates a speculative business model due to a lack of commercial products and intense competition. The company leverages an Israeli scientific base to develop therapies for the treatment of NAFLD. Analysts' valuations based on n+1 net profit dynamics visualize the fundamental trend, where the value of 80.70 represents the most recent figure. Growth is driven by patent acquisitions and partnerships for Aramchol trials.
Comprehensive metric breakdowns and analytics for Galmed Pharma (GLMD)

This indicator aggregates analyst consensus forecasts for earnings per share growth rates, measuring market expectations regarding future business profitability. By analyzing the trend of expected net income per share, an investor can assess the impact of inelastic demand for the drug Aramchol and the pricing power of Galmed Pharmaceuticals (GLMD) on the company's future financial results.